Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Elaris Flexco has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, CHO, DAVID H, within 1 distinct art unit. The prosecution profile is currently focused on this 1 pending office action. This concentration suggests a focused patent portfolio where all active matters are consolidated under a single point of review at the patent office.
The busiest examiner for the portfolio is CHO, DAVID H, who is responsible for 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy does not require coordination across multiple divisions. The presence of 1 pending office action indicates a prosecution pipeline that is currently limited to a single matter. This allows for a response strategy tailored to the specific requirements of the 1 distinct examiner. Practitioners should note that the company's immediate patent office interactions are limited to this specific examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 1 | 31.9% | +67.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476600 | METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIODES DIFFICILE INFECTIONS | CHO, DAVID H | 40d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18476600 | METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIODES DIFFICILE INFECTIONS | CHO, DAVID H | 40d |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18476600 | METHODS AND COMPOSITIONS FOR TREATING CLOSTRIDIODES DIFFICILE INFECTIONS | CHO, DAVID H | 1693 | §102§103§112 | Final Rejection | 40d | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialElaris Flexco has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
David H Cho has the most, with 1 of Elaris Flexco's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
